VRG Therapeutics Announces Monthly Dosing for Its Lead Program Targeting Kv1.3 for the Treatment of Atopic Dermatitis and Other Chronic Inflammatory Diseases
People
October 5, 2023
By VRG Therapeutics
New member to the team: Lili Kovanecz-Jármi
Conference
September 25, 2023
By VRG Therapeutics
Meet in Italy for Life Sciences - Startup Breeding 2023
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.